Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Vincerx Pharma, Inc. (VINC) had Normalized Income after Taxes of $-5.00M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-5.00M |
|
-- |
|
-- |
|
$3.33M |
|
$-3.33M |
|
$-1.67M |
|
$-5.00M |
|
$-5.00M |
|
$-5.00M |
|
$-5.00M |
|
$-5.00M |
|
|
Normalized Income after Taxes |
$-5.00M |
$-3.33M |
|
$-3.33M |
|
3.58M |
|
3.58M |
|
$-1.40 |
|
$-1.40 |
|
| Balance Sheet Financials | |
$4.69M |
|
-- |
|
-- |
|
$4.69M |
|
$2.62M |
|
-- |
|
-- |
|
$2.62M |
|
$2.07M |
|
$2.07M |
|
$2.07M |
|
5.23M |
|
| Cash Flow Statement Financials | |
$-4.45M |
|
-- |
|
$3.86M |
|
$5.07M |
|
$4.52M |
|
$-0.55M |
|
$0.43M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.79 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.45M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-242.01% |
|
-242.01% |
|
-106.70% |
|
-242.01% |
|
$0.39 |
|
$-1.24 |
|
$-1.24 |
|